Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm, Leuk Res, vol.73, pp.21-23, 2018. ,
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2017. ,
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches, Br J Haematol, vol.174, issue.2, pp.188-202, 2016. ,
,
, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation, Blood, vol.121, issue.3, pp.440-446, 2013.
Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis, Clin Lymphoma Myeloma Leuk, vol.18, issue.11, pp.703-709, 2018. ,
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2008. ,
Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia, Br J Haematol, vol.145, issue.5, pp.624-636, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00451257
Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis, Cytometry A, vol.81, issue.8, pp.718-724, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00718156
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study, Haematologica, vol.98, issue.2, pp.239-246, 2013. ,
Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles, Ann Hematol, vol.98, issue.9, pp.2221-2222, 2019. ,
Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm, Am J Surg Pathol, vol.43, issue.10, pp.1429-1437, 2019. ,
TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis, Am J Clin Pathol, vol.122, issue.2, pp.307-313, 2004. ,
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients, Am J Surg Pathol, vol.38, issue.5, pp.673-680, 2014. ,
A druggable TCF4-and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm, Cancer Cell, vol.30, issue.5, pp.764-778, 2016. ,
The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells, Leukemia, vol.20, issue.8, pp.1439-1441, 2006. ,
Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients, Am J Surg Pathol, vol.34, issue.1, pp.75-87, 2010. ,
AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies' and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition, Leukemia, vol.28, issue.8, pp.1606-1616, 2014. ,
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile, Oncotarget, vol.6, issue.22, pp.19204-19216, 2015. ,
CD56(1) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique, Blood, vol.99, issue.1, pp.4154-4159, 2002. ,
Simultaneous deletion of 3"ETV6 and 5"EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review, Mol Cytogenet, vol.9, issue.1, p.23, 2016. ,
Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion, Blood, vol.118, issue.17, pp.4591-4594, 2011. ,
Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events, Leuk Res, vol.73, pp.86-94, 2018. ,
Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms, Blood, vol.127, issue.24, pp.3040-3053, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01920364
Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm, Leukemia, vol.31, issue.7, pp.1629-1633, 2017. ,
KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm, Cancer Genet, vol.208, issue.9, pp.464-467, 2015. ,
Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: a borderline case between acute monocytic leukemia, J Clin Exp Hematop, vol.52, issue.2, pp.107-111, 2012. ,
Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms, Cancer Genet, vol.206, issue.7-8, pp.293-298, 2013. ,
Identification of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation, Blood Cancer J, vol.5, issue.4, p.301, 2015. ,
Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm, Nat Commun, vol.10, issue.1, p.3943, 2019. ,
, Nat Commun, vol.10, issue.1, p.1653, 2019.
t(6;8)(p21;q24)in blastic plasmacytoid dendritic cell neoplasma, 2013. ,
Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases, Leuk Res, vol.26, issue.7, pp.693-698, 2002. ,
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response, Leukemia, vol.32, issue.12, pp.2590-2603, 2018. ,
An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality, Histopathology, vol.73, issue.5, pp.767-776, 2018. ,
A rare case of blastic plasmacytoid dendritic cell neoplasm with aberrant immunophenotypic profile and unusual cytogenetics, Am J Clin Pathol, vol.146, 2016. ,
Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations, Br J Haematol, vol.181, issue.3, p.305, 2018. ,
8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms, Leuk Res, vol.66, pp.73-78, 2018. ,
Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study, Br J Haematol, vol.179, issue.5, pp.781-789, 2017. ,
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm, Blood, vol.125, issue.23, pp.3559-3562, 2015. ,
Blastic plasmacytoid dendritic cell leukemia successfully treated by autologous hematopoietic stem cell transplantation to a remission of 48-month duration, Case Rep Hematol, p.471628, 2013. ,
Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD41/CD561 hematodermic neoplasm, Leuk Lymphoma, vol.53, issue.8, pp.1633-1637, 2012. ,
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm, Haematologica, vol.102, issue.11, pp.1861-1868, 2017. ,
Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm, Ann Hematol, vol.98, issue.6, pp.1525-1527, 2019. ,
Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm, N Engl J Med, vol.379, issue.15, pp.1479-1481, 2018. ,
Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report, Medicine, vol.96, issue.51, p.9452, 2017. ,
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies, Am J Hematol, vol.93, issue.3, pp.401-407, 2018. ,
Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax, Cancer Discov, vol.7, issue.2, pp.156-164, 2017. ,
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark, Blood, vol.134, issue.8, pp.678-687, 2019. ,
Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate, Ann Hematol, vol.96, issue.4, pp.681-682, 2017. ,
Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate, Ann Hematol, vol.98, issue.3, pp.801-803, 2019. ,
Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine ,
, Rinsho Ketsueki, vol.59, issue.12, pp.2567-2573, 2018.
Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases, Leuk Lymphoma, vol.57, issue.11, pp.2720-2722, 2016. ,
Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine, Eur J Haematol, vol.93, issue.1, pp.81-85, 2014. ,
Novel pathways and potential therapeutic strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond, Curr Hematol Malig Rep, vol.12, issue.6, pp.510-512, 2017. ,
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients, Blood, vol.124, issue.3, pp.385-392, 2014. ,
First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases, J Hematol Oncol, vol.11, issue.1, p.61, 2018. ,
Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm, N Engl J Med, vol.380, issue.17, pp.1628-1637, 2019. ,
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells, Blood Adv, vol.2, issue.8, pp.848-858, 2018. ,